Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rovalpituzumab tesirine + nivolumab + ipilimumab
- Development stage
- Discontinued
- Lead developer
- AbbVie
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
A combination therapy consisting of **rovalpituzumab tesirine** (an antibody-drug conjugate that targets DLL3 on tumor cells), **nivolumab** (an anti–PD-1 checkpoint inhibitor antibody), and **ipilimumab** (an anti–CTLA-4 checkpoint inhibitor antibody). Rovalpituzumab tesirine delivers cytotoxic agents directly to DLL3-expressing tumor cells, inducing cell death. Nivolumab blocks the PD-1 pathway on T cells, preventing antigen-mediated immune suppression and restoring antitumor T cell activity. Ipilimumab blocks CTLA-4, further enhancing T cell activation and proliferation. This combination is being explored mainly in the treatment of neuroendocrine tumors, including small cell lung cancer, aiming to potentiate immune response and deliver targeted cytotoxicity for improved antitumor effect.
- Other names
- rovalpituzumab tesirinenivolumabipilimumab
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)DLL3 (Delta-like ligand 3)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on rovalpituzumab tesirine + nivolumab + ipilimumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rovalpituzumab tesirine + nivolumab + ipilimumab.